Skip to main content

Featured Article: Tankyrases as modulators of pro-tumoral functions: molecular insights and therapeutic opportunities

New Content ItemTankyrase 1 (TNKS1) and tankyrase 2 (TNKS2) are two homologous proteins that are gaining increasing importance due to their implication in multiple pathways and diseases such as cancer. TNKS1/2 interact with a large variety of substrates through the ankyrin (ANK) domain, which recognizes a sequence present in all the substrates of tankyrase, called Tankyrase Binding Motif (TBM). One of the main functions of tankyrases is the regulation of protein stability through the process of PARylation-dependent ubiquitination (PARdU). Nonetheless, there are other functions less studied that are also essential in order to understand the role of tankyrases in many pathways.  

In this review, the Authors concentrate in different tankyrase substrates and we analyze in depth the biological consequences derived of their interaction with TNKS1/2. They also examine the concept of both canonical and non-canonical TBMs and finally, we focus on the information about the role of TNKS1/2 in different tumor context, along with the benefits and limitations of the current TNKS inhibitors targeting the catalytic PARP domain and the novel strategies to develop inhibitors against the ankyrin domain. Available data indicates the need for further deepening in the knowledge of tankyrases to elucidate and improve the current view of the role of these PARP family members and get inhibitors with a better therapeutic and safety profile.

Aims and scope

Journal of Experimental & Clinical Cancer Research is an online peer-reviewed journal that provides a high-quality forum for all aspects of basic, clinical and translational work in oncology.

Please click here to read more.

Editor-in-Chief

Mauro Castelli, Regina Elena National Cancer Institute, Italy

If you would like to contact Journal of Experimental & Clinical Cancer Research, please send an email to: 

editorialjeccr@gmail.com

Articles

Springer Nature Oncology Portfolio

Discover the range of academic oncology titles at Springer Nature here.

Call for papers: Organoids as clinically relevant models to tailor precision medicine in cancer treatment

Organoid teaser image

Journal of Experimental & Clinical Cancer Research is delighted to announce a new thematic series focused on:

Organoids as clinically relevant models to tailor precision medicine in cancer treatment.

The 2023 Special Issue will accept Research Articles and Reviews regarding the latest highlights on this topic. Submit here.

  • Submission opens: 1st January 2023
  • Submission deadline: 31st December 2023

Click here to view this collection. Click here to access all thematic series published to date in Journal of Experimental & Clinical Cancer Research.

Call for papers: CRISPR-Cas9 system, the next generation in cancer therapy and target discovery

New Content Item

Journal of Experimental & Clinical Cancer Research is delighted to announce a new thematic series focused on:

CRISPR-Cas9 system, the next generation in cancer therapy and target discovery

The Special Issue will accept Research Articles and Review in this topic.  Submit here

  • Submission opens: 1st April 2023
  • Submission deadline: 31st March 2024

Click here to view this collection. Click here to access all thematic series published to date in Journal of Experimental & Clinical Cancer Research.

Follow JECCR on Social Media

Social Media IconsTwitter

Facebook

LinkedIn

Follow JECCR's social media accounts to be kept up-to-date with the latest articles, collections and journal news!

Recognising Editorial Excellence

SN Editorial Excellence badgeJournal of Experimental & Clinical Cancer Research is a top rated Springer Nature journal. Prof. Mauro Castelli and the editorial team performed in the top percentile of journals based on data collected from the Journal Author Satisfaction Survey. We are recognising extraordinary editors for their commitment and passion to their journals. Read more about editorial excellence here.

Reviewer Acknowledgement and New Recruitment

The Editor-in-Chief of Journal of Experimental & Clinical Cancer Research would like to thank all of our reviewers who have contributed to the journal and is looking for new reviewers to assess manuscripts. For consideration, please send your CV with keywords and expertise to editorialjeccr@gmail.com

Archival content

Journal of Experimental & Clinical Cancer Research has been publishing since 1982.  Prior to publishing with BioMed Central from 2008, Journal of Experimental & Clinical Cancer Research was published in print.  For enquiries about previous content, please contact us on: 

editorialjeccr@gmail.com


Annual Journal Metrics

  • 2022 Citation Impact
    11.3 - 2-year Impact Factor
    11.5 - 5-year Impact Factor
    1.870 - SNIP (Source Normalized Impact per Paper)
    2.413 - SJR (SCImago Journal Rank)

    2022 Speed
    5 days submission to first editorial decision for all manuscripts (Median)
    97 days submission to accept (Median)

    2022 Usage 
    2,694,347 downloads
    4,666 Altmetric mentions